Skip to main content
main-content

Exenatide

News

12-08-2017 | Cardiovascular outcomes | News

Meta-analysis may support cardioprotective class effect for GLP-1 receptor agonists

A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.

09-15-2017 | Exenatide | EASD 2017 | News

EXSCEL: Near miss for exenatide cardioprotection

The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.

09-13-2017 | Glucagon-like peptide-1 agonists | EASD 2017 | News

Incretins research update

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

Read more

Related topics

Superior

Related

Opinion

10-23-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.

In depth

10-17-2017 | Glucagon-like peptide-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

Journal articles and book chapters

10-23-2017 | Cardiovascular disorders | Review | Article

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

The authors develop regional expert consensus recommendations with aim of improving the care of patients with type 2 diabetes at high cardiovascular risk in Central and Eastern Europe.

Schernthaner G et al. Cardiovasc Diabetol 2017;16:137. doi:10.1186/s12933-017-0622-7

10-11-2017 | Cardiovascular disorders | Review | Article

Updates on cardiovascular outcome trials in diabetes

This review summarizes the results of the DEVOTE, CANVAS, EXSCEL, and ACE trials that tested the cardiovascular safety of insulin degludec, canagliflozin, once-weekly exenatide, and acarbose, respectively.

Schnell O et al. Cardiovasc Diabetol 2017;16:128. doi:10.1186/s12933-017-0610-y

09-04-2017 | Nephropathy | Review | Article

GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes

Muskiet et al. review the role of glucagon-like peptide 1 (GLP-1) on glucose metabolism, the gut–renal axis, classical renal risk factors, and renal end points in trials of GLP-1 receptor agonists for type 2 diabetes.

Nat Rev Nephrol 2017; 13: 605–628. doi: 10.1038/nrneph.2017.123

Authors:
Marcel H. A. Muskiet, Lennart Tonneijck, Mark M. Smits, Michaël J.B. van Baar, Mark H. H. Kramer, Ewout J. Hoorn, Jaap A. Joles, Danië H. van Raalte
image credits